ICON EYECARE SPRING IS IN THE AIR

APRIL 2021



DRY EYE TREATMENTS

Take a look into cutting-edge treatment options ICON offers for patients with dry eye.

LASER FLOATER THERAPY (LFT)

Learn more about laser therapy for floaters.

PLEASE SEND A WARM WELCOME TO DR. SANDERS!

Dr. Sanders has officially joined ICON Eyecare! As of March 1st, 2021, Dr. Sanders is seeing patients and operating. Dr. Sanders currently is working two days a week and we are excited to have her.

Dr. Sanders practices general ophthalmology and is a meticulously safe cataract surgeon who is up to date on the latest and greatest technologies. Dr. Sanders also specializes in cosmetic procedures of the face/neck. She currently performs Botox injections of the face/neck and IPL treatments geared towards treating sun spots, pigmentation abnormalities, hemangiomias and other pigment derived lesions. We will be rolling out a whole cosmetic line of in-office procedures and skin care. We are looking to add Clear and Brilliant Laser resurfacing and dermabrasion, and we will be adding a line of skin care products that Dr. Sanders had developed in her previous practice (these are just a taste of things we are looking to add). Refer a patient to Dr. Sanders today!



FDA CLINICAL TRIALS

An overview of all the clinical trials that ICON is participating in, and how you can be involved!

APRIL 2021

ICON is proud to offer four new treatment options for dry eye:

- 1. Plasma Rich in Growth Factors (PRGF) drops
- 2. Meibomian Gland Probing (MGP)
- 3. Intense Pulsed Light Therapy (IPL)
- 4. NOV03 (see FDA clinical trials)



Intense Pulsed Light Therapy-Coming Soon!


Used for meibomian gland dysfunction(MGD), it's a laser device that emits short bursts of light to skin around eyes. This is particularly beneficial for patients with <u>telangiectasias</u> leading to inflammation at the lid margin and can be combined with LipiFlow to maximize results. . Patients need four sessions spaced 2-3 weeks apart. This will be available to patients in a few months!

PRGF= higher quality, concentrated serum tears used for late stage dry eye or poor cornea healing. One blood draw results in a three month supply of eyedrops. (We still do normal serum tears, but these have been invaluable for refractory cases as well!). To our knowledge, we are the only clinic in Colorado to offer PRGF for patients with severe dry eye.



MEIBOMIAN GLAND PROBING:

Recommended for patients with obstructive meibomian gland dysfunction. Dr Holt inserts a small wire probe in each mebomian gland. Combined with Lipiflow, it improves gland function. We will likely be using this less with the addition of IPL.



LFT (Laser Floater Therapy)-

Also known as laser floater treatment or vitreolysis, LFT is a non-invasive procedure that can eliminate the visual disturbance caused by eye floaters. It uses a YAG laser that is specifically designed to break up floaters, while maintaining a significantly high level of safety for those individuals where a vitrectomy could be too risky.

Dr. Tubbs is currently accepting referrals for LFT evaluations. Please see the included insert that goes into more detail about the LFT procedure.

It's exciting to offer truly cutting edge treatments to our patients. All patients are thoroughly consented, and all patients receive a stipend or subsidies for participating in the trials. If you have any questions regarding any of the clinical trials, please contact our research coodinator, Chris Bosch, at (970)205-9555.

OTHER QUESTIONS?

IF YOU HAVE ANY QUESTIONS/COMMENTS/CONCERNS, PLEASE CONTACT SHELBY CROSSWHITE AT:

(970)325-2426 OR SHELBY.CROSSWHITE@ICONEYECARE.COM

Keep Up With Us On Social Media!



Current Clinical Trials

- iDose by Glaukos (Phase III FDA trial): a device that delivers medication to the anterior chamber of the eye to reduce IOP's. We are in the final stages of recruitment and are in need of referrals! You can receive \$500 if the patient is a candidate for the study.
- 2. Beacon Aqueous Microshunt (Phase I/II FDA trial): a shunt designed to lower IOP's in refractory glaucoma patients. We currently have four patients enrolled and are waiting for FDA approval to implant additional subjects (Canada has now been approved to implant patients).
- 3. NOV03 (Phase III FDA trial): a medication for the treatment of dry eye disease associated with Meibomian Gland Disease that is currently over the counter in Germany. We are currently enrolling patients!
- 4. APP13007 (FDA Phase III trial): A clobetasol steroid drop for inflammation and pain after cataract surgery. We are currently enrolling patients!
- 5. Vivity Toric IOL (After market/post FDA approval trial): After-market study to evaluate patient satisfaction and visual outcomes after bilateral implantation of Vivity Toric IOL. We are currently enrolling patients!